An interventional study of Ferrous Sulphate 65 mg and Curcumin in Iron Deficiency (Without Anemia), sponsored by University of Westminster. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-10.
Sponsored by University of Westminster · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Iron Deficiencies with a site in United Kingdom — 2 open to participants now, 2 under way, none of them phase 3. Iron Deficiencies · United Kingdom.
Among the 22 studies in Iron Deficiencies with a site in United Kingdom, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2018, is one of 11 with no phase, and was the 19th registered.
386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.
Browse Iron Deficiencies studies →2 of the 22 studies in Iron Deficiencies with a site in United Kingdom are open now. Recruiting first, the newest first:
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Quadram Institute Bioscience · Sites in United Kingdom
Ages 18–60 · Women only · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 2004; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 99 across 301 interventional studies indexed under Iron Deficiencies.
Median enrollment 50 across the 19 interventional studies, 379 across the 3 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
University of Westminster is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
University of Westminster has 2 studies filed under Iron Deficiencies — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Iron Deficiencies with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
INTRODUCTION: Iron is a vital nutrient for many physiological processes including DNA production, oxygen transport and neuronal processes. However, several factors limit iron absorption including: limited bioavailability of iron (dietary or supplementation sources), can be subject to dietary iron inhibitors (e.g. calcium). Excess iron can cause cellular oxidative stress in the body.
Curcumin is an active component found in turmeric, known for its anti-oxidant and anti-inflammatory properties. Co-administration of iron and curcumin may influence iron, inflammatory status and/or neurotrophic markers in the body.
Intervention study with five parallel treatment groups in a randomised, double-blind, placebo-controlled design.
Study population: Healthy Participants (Male or Female) will receive daily supplements (active or equivalent placebos) for 6 weeks (42 days)
Biological samples (blood and urine samples) are collected at baseline visit (day 1), mid-point (day 21) and end-point (day 42). In addition, pertinent questionnaires (Visual Analogue Scale-Fatigue [VAS-F] and oral iron supplement questionnaire will be collected at the aforementioned time points.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ferrous Sulphate (65 mg/day elemental iron) and Curcumin 500 mg/day
Dietary Supplement: Ferrous Sulphate 65 mg · Dietary Supplement: Curcumin
Ferrous Sulphate (65 mg/day elemental iron) and Placebo (Curcumin placebo \[cellulose\])
Dietary Supplement: Ferrous Sulphate 65 mg · Other: Placebo (Curcumin)
Placebo (Ferrous Sulphate placebo \[cellulose\]) and Placebo (Curcumin placebo \[cellulose\])
Other: Placebo (Ferrous Sulphate) · Other: Placebo (Curcumin)
Ferrous Sulphate (18 mg/day elemental iron) and Placebo (Curcumin placebo \[cellulose\])
Other: Placebo (Curcumin) · Dietary Supplement: Ferrous Sulphate 18mg
Ferrous Sulphate (18 mg/day elemental iron) and Curcumin 500 mg/day
Dietary Supplement: Curcumin · Dietary Supplement: Ferrous Sulphate 18mg
Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content) Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach) At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules
Also known as: Ferrous Sulfate
HydroCurc™ 500 mg formulated curcumin At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)
Also known as: Turmeric, Curcuma longa
Microcrystalline cellulose Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)
Microcrystalline cellulose Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)
Oral ferrous salt supplement Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content) Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach) At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules
Also known as: Ferrous Sulfate
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated inflammation
Marker: Interleukin 6 (pg/mL), Interleukin 10 (pg/mL), Interleukin 1 beta (pg/mL)
Time frame: Change in Interleukin 6, Interleukin 10 and Interleukin 1 beta (ELISA) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated inflammation
Tumour Necrosis Factor alpha (pg/mL)
Time frame: Change in Tumour Necrosis Factor alpha (ELISA) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated inflammation
Marker: C-Reactive Protein (g/L)
Time frame: Change in C-Reactive Protein (immunoassay) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated lipid peroxidation
Marker: thiobarbituric acid reactive substances (μM)
Time frame: Change in thiobarbituric acid reactive substances (ELISA) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated acute iron absorption
Marker: serum iron (μmol/L)
Time frame: Change in serum iron (colorimetric analyser) from 0 and 180 minutes following supplementation
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated acute iron absorption
Marker: total iron binding capacity (μmol/L)
Time frame: Change in total iron binding capacity (colorimetric analyser) from 0 and 180 minutes following supplementation
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status
Marker: serum iron (μmol/L)
Time frame: Change in serum iron (colorimetric analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status
Marker: total iron binding capacity (μmol/L)
Time frame: Change in total iron binding capacity (colorimetric analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status
Marker: Ferritin (ng/mL)
Time frame: Change in ferritin (immunoassay) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status
Marker: Haemoglobin (g/dL)
Time frame: Change in haemoglobin (whole blood analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status
Marker: Red blood cells (M/μL)
Time frame: Change in red blood cells (whole blood analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated neurotrophic levels
Marker: Brain derived neurotrophic factor (BDNF) (ng/mL)
Time frame: Change in BDNF (ELISA) from baseline to endpoint from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated gastrointestinal effects
Subjective analysis including: Oral Iron Supplement Questionnaire
Time frame: Change in reported subjective gastrointestinal effects from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated perception of fatigue
Subjective analysis including: Visual Analogue Scale for Fatigue (VAS-F). Scores range from 0 to 100 (the higher the score the greater the level of fatigue)
Time frame: Change in VAS-F from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated perception of fatigue
Subjective analysis including: Fatigue Severity Scale (FSS). The total score of all answers indicates level of fatigue (a total score above ≥ 36 indicates fatigue).
Time frame: Change in FSS from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2018 to primary completion in Nov 2019, 15 months.
Of 77 non-industry interventional studies with no phase under Iron Deficiencies, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 15 months is above that.
Counting every sponsor, half of 89 studies reached it within 10 months; a quarter within 5 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Curcumin
University of Westminster